Pfizer exists to develop new, safe medicines to treat serious diseases and make them available to those in need. They strive to positively impact global health through philanthropy focused on increasing access to medicines, healthcare services, and capacity building. Currently, Pfizer prioritizes research in immunology, oncology, cardiovascular, neuroscience, and vaccines through small molecules, biologics and vaccines. They have expanded research and manufacturing facilities globally to grow their reputation and market value.
2. WHY DOES PFIZER EXIST?
We exist due to a single goal: Your Health.
That's why we're dedicated to developing new,
safe medicines to prevent and treat the world's
most serious diseases. And why we are making
them available to the people who need them
most. We believe that from progress comes
hope and the promise of a healthier world.
3. HOW DO WE DO WHAT WE BELIEVE
IN?
At Pfizer, we strive to positively impact the health of the people
around the world. Our philanthropy is focused on investing the full
range of the company’s resources- People, skills, expertise and
funding- to broaden access to medicines and strengthen
healthcare delivery for undeserved people around the world.
Improving access to medicines and health services.
Expanding healthcare worker training and patient education on
diseases.
Strengthening the capacity of healthcare organizations to support
diagnosis and care.
Advocating and sharing best practices to improve healthcare for
the under privileged people through direct engagements with
4. WHAT DO WE DO TO CHANGE THE
WORLD?
Right from the Civil War in 1862 to now. Pfizer has
been innovating in the field of pharmaceuticals- be it
the first company to produce citric acid on a large
scale to the latest launch of a biosimilars in Arthritis.
We have been in the healthcare industry when the
people needed us the most. We gave them penicillin
then, and now, we’re the 3rd biggest company to
provide medicines all over the world. We also treat
people around the globe with our excellent employees
and medical devices.
5.
6. LET’S BUILD SOMETHING NEW
In the making of a new molecule, the first step is to develop a
project that gives quicker outcome, thus providing a benefit for
lower cost, in a more predictable way. To put it more properly,
we can say..
“You can miss expectations with a below
average execution of an excellent strategy, but
you can exceed expectations with excellent
execution of an average strategy”
7. DEMANDS AND STRATEGY
The initiation of a project is done by understanding the necessities of
the current pharmaceutical market and then coming up with a plan to
provide the world with a cure.
Once a problem is apprehended, the organization has to strategize a
new project which would help the innovation of a new molecule. The
strategy is planned out on various factors.
MANPOWER MACHINERY
RISKS
RESOURCES FINANCES
8. PLANNING THE PROJECT
Formation of Team with a Leader
Scope of the Project
Work Structure
Time/Cost Trade-Offs
Stakeholder Planning
10. AGGREGATION OF RESOURCES
The resources at hand must be monitored and
used wisely.
Manpower and Machinery available are inversely
proportional to the amount of time required to
complete the project.
11. IDENTIFYING THE RISKS
Project Risks
Schedule
Poor
Estimation
Insufficient
Resources
Requirement
Uncertainties
Cost
Lack of
Funding
Inflation Labour Costs
Scope
New Tests
New
Technology
Regulatory
Changes
13. PROJECT IMPLEMENTATION
Project Implementation is the stage in which the
project turns into reality in order to produce
“Deliverables”
Deliverables include Products, Services and Project
Management documents
The steps to produce deliverables depend on the
type of project
14. PROJECT IMPLEMENTATION
Basic Requirements
• A project plan.
• Financial, Material and Human resources.
• Project Manager
Basic Steps
• Installation of systems and Trainings
• Project monitoring with regard to cost,
value of work and time.
• Effective change control.
• Updating of project schedule after
slippages in time and cost.
• Coordination with the head office,
suppliers, contractors and project
members.
• Documentation
15. REVIEW OF THE COMPLETED PROJECT
A project is completed when all objectives are met
Reporting
Closure Phase
Review
Gate
Project Managers
Access performance
Areas of deviation
Possible problems
Final
Deliverables
16. CLOSURE PHASE
Handing over the project reports
Releasing the final deliverables/ Launching the product in the market
Post market surveillance (Evaluation)
Release of project resources
Terminating contracts and doing final payments if any
Communicating project closure to all stakeholders
17. CHALLENGES IN A PROJECT
The industry average to bring a new drug to market is
15 years. Each year of discovery and development
entails billions of dollars in research and testing.
Pharmaceutical companies like Pfizer must make
informed decisions about which prospective drugs
show the most promise, and focus their resources
accordingly, to be competitive. We present you a case
on the challenges faced by Pfizer Australia and how
they came to a solution.
18. DISCRETIONARY SPENDS:
MAJOR ACHIEVEMENT IN
AUSTRALIA
One of the nations leading health care partners.
Employees more than 1,100 staff in Australia.
Australia’s most innovative and valued health care
committee.
19. THE OBSTACLES
Loss of patent production of key products.
Change in strategy was the need of the hour.
Excess of 100 projects.
No clear idea of what the project was.
“Accidental Project Managers”.
Lack of consistency.
Multiple projects being run with conflicting or impacting
objectives.
20. TO TACKLE THOSE CHALLENGES
Adaptra was engaged to review its Project
management and execution capabilities.
Lead to the formation of Project Management
Organization, which was responsible of the following:
•Return on discretionary spend.
•Increase decision-making capabilities.
•Improve cross-functional collaboration.
•Organisational cultural change.
•Increase employee satisfaction.
21. WE’VE MADE IT!
Establishment of the PMO within six months.
Reduce the 100+ projects to a prioritized and manageable
‘Top 40’.
Optimized the use of limited resources.
Managers are focused on doing ‘the right things right’.
Established a project management community.
“The PMO provided people with the skills, confidence and advice to help our
managers execute their projects – I can’t live without our PMO now, and
Adaptra have made that possible.”
-Jane Frost
Director, Pfizer Australia
22. CURRENT PROJECT TRENDS
Pfizer is prioritizing its research and development
efforts in areas with the greatest scientific and
commercial promise: immunology and inflammation,
oncology, cardiovascular and metabolic diseases,
neuroscience and pain, and vaccines. Through major
research efforts across multiple modalities — including
small molecules, biologics and vaccines — Pfizer is
developing the medical solutions that will matter most
to the people we serve. Specialized efforts in
biosimilars as well as rare diseases also illustrate our
dedication to developing and delivering innovative
medicines and vaccines that will benefit patients
24. PHARMACEUTICAL INDUSTRY
PROJECTS
A company grows by the growth of its employees, as well as
their assets. There is a serious need of expansion of the
research and the manufacturing facilities if a company wants
to grow in reputation and market value. The recent
development in the facilities of Pfizer include:
Biotechnology Centre at China for the development of
biosimilars in Asia.
Pfizer Biologic’s Clinical Manufacturing facility, USA.
Pfizer Bulk Pharmaceutical Factory, Singapore.
Pfizer Biotechnology Campus, Ireland.
